International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 5 Sep-Oct 2023, pp: 833-840 www.ijprajournal.com ISSN: 2249-7781

Next-Generation Vaccines: Advancements in mRNA-Based Immunization Strategies

[1]Vrushali Petkar, [2]Ashwini Yeole and [3]Suvarna Chavan
[1,3]*Asst. Prof., Department of Zoology, K.J. Somaiya College of Art's, Commerce and Science, Kopargaon, Maharashtra, India*
[2]*Asst. Prof., Department of Botany, K.J. Somaiya College of Art's, Commerce and Science, Kopargaon, Maharashtra, India*
Corresponding Author: [1]Vrushali Petkar

Submitted: 01-10-2023 Accepted: 10-10-2023

ABSTRACT: The landscape of vaccinology is undergoing a profound transformation, driven by recent studies and research in the realm of mRNA-based immunization strategies. This research review delves into the revolutionary advancements in mRNA vaccines, exploring their mechanisms, clinical successes, and prospects. Messenger RNA (mRNA), once regarded as a passive messenger in the central dogma of biology, has risen to prominence as a versatile tool for instructing cells to produce target proteins, including antigens. This paradigm shift has paved the way for mRNA-based vaccines, a novel class of vaccines that harness synthetic RNA to encode specific antigens. When administered, these vaccines instruct host cells to generate antigenic proteins, thereby triggering robust immune responses. The adaptability and rapid development capabilities of mRNA vaccines have positioned them as game-changers in the field. The COVID-19 pandemic catalyzed mRNA vaccines, with Pfizer-BioNTech and Moderna vaccines achieving remarkable efficacy in clinical trials. These successes underscored the potential for mRNA vaccines to provide rapid and effective responses to emerging infectious diseases. Beyond infectious diseases, recent research has explored the applications of mRNA vaccines in personalized cancer immunotherapy, marking a pivotal shift in cancer treatment approaches. Despite these remarkable advancements, challenges persist. Storage and distribution logistics, safety concerns, and the imperative of equitable vaccine access remain critical considerations for the future of mRNA vaccines. In conclusion, recent studies have illuminated a promising path forward in vaccinology through mRNA-based immunization strategies. These innovations hold the potential to revolutionize our approach to infectious diseases, cancer treatment, and global health challenges. However, addressing the associated challenges and ensuring equitable access to these transformative vaccines will be pivotal as we navigate this new frontier in healthcare.

KEYWORDS:m-RNA Vaccines, Immunization, Covid-19, RNA revolution

I. INTRODUCTION

The relentless pursuit of effective vaccines against infectious diseases has been a hallmark of biomedical research for centuries. From the eradication of smallpox to the control of polio, vaccines have played a pivotal role in saving lives and reducing the burden of morbidity worldwide.[1] Yet, the field of vaccinology is far from stagnant. Recent years have borne witness to a transformative breakthrough—a paradigm shift in vaccine development that promises to reshape our approach to immunization.[2] This transformation is epitomized by the emergence of mRNA-based immunization strategies. While vaccines have traditionally relied on weakened or inactivated pathogens or subunits to elicit immune responses, mRNA vaccines represent a novel and versatile approach.[3] At their core, these vaccines harness the fundamental biological process of messenger RNA (mRNA) to instruct cells to produce target antigens, thereby stimulating a potent immune response.[4] This profound shift in vaccine design holds the potential to revolutionize not only the prevention of infectious diseases but also our approach to cancer treatment and emerging health threats. The RNA revolution, marking a paradigmatic change in our understanding of RNA's role in molecular biology, has paved the way for the development of mRNA vaccines.[5] Long relegated to the status of a passive intermediary in the central dogma of biology, messenger RNA is now recognized as a dynamic and central player.[6] This newfound appreciation stems from the realization that mRNA carries the

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 5 Sep-Oct 2023, pp: 833-840 www.ijprajournal.com ISSN: 2249-7781

genetic instructions for protein synthesis from the DNA in the cell nucleus to the ribosomes, where protein production occurs. The adaptability and programmability of mRNA make it an ideal candidate for vaccine development, as it can be engineered to encode specific antigens, mimicking the pathogens of interest without causing disease.[7] mRNA vaccines, the embodiment of this RNA revolution, are a class of vaccines that employ synthetic mRNA molecules to encode target antigens. When administered, these synthetic mRNA molecules serve as templates for antigen production within host cells, initiating immune responses against the encoded antigen.[8] This groundbreaking approach circumvents the need to cultivate and manipulate live pathogens or produce complex subunit vaccines, offering an agile and rapid response to emerging threats.[9,10] Recent studies have showcased the exceptional adaptability of mRNA vaccines, positioning them as powerful tools in the fight against infectious diseases.[11,12] The remarkable trajectory of mRNA-based vaccines into the spotlight was catalyzed by the global COVID-19 pandemic. As the SARS-CoV-2 virus swiftly spread across the globe, researchers faced an urgent imperative to develop safe and effective vaccines. In this critical juncture, mRNA vaccines rose to the occasion, demonstrating their potential to expedite vaccine development without compromising safety or efficacy.[13] Two mRNA vaccines, namely the Pfizer-BioNTech and Moderna vaccines, achieved unprecedented success in clinical trials, garnering emergency use authorizations and marking a historic turning point in vaccinology. These achievements not only provide hope in the ongoing battle against COVID-19 but also serve as a testament to the adaptability and potential of mRNA-based vaccines.[14] Beyond their application in infectious disease control, mRNA vaccines have embarked on an intriguing journey into the realm of personalized cancer immunotherapy. Recent research studies have highlighted the capacity of mRNA vaccines to stimulate immune responses against tumor-specific antigens.[15] This therapeutic potential has the potential to transform cancer treatment paradigms, opening avenues for highly tailored and precise interventions. By encoding tumor-specific antigens, mRNA vaccines can engage the immune system in recognizing and eliminating cancer cells, offering new hope for patients facing malignancies that have traditionally been challenging to treat. The advancements in mRNA vaccines extend further into the realm of emerging infectious diseases.[16] Recent studies have underscored the versatility of this vaccine platform in rapidly responding to new and unforeseen health threats. Exemplified by their application in Zika and Ebola vaccine development, mRNA vaccines offer a nimble approach to pandemic preparedness. This adaptability is particularly crucial in the face of emerging pathogens with pandemic potential, allowing for the rapid design and production of vaccines tailored to the specific threat. While the promise of mRNA-based immunization strategies is undeniable, it is essential to recognize the challenges that accompany this transformative approach.[17] Storage and distribution logistics, including the need for ultra-low-temperature storage in some cases, present formidable hurdles, particularly in resource-limited settings. Safety concerns, including rare instances of anaphylaxis, necessitate ongoing research to understand the underlying mechanisms and mitigate potential risks. Furthermore, the imperative of equitable access to mRNA vaccines on a global scale demands international collaboration and technology transfer to bridge disparities in vaccine distribution.[18] As we navigate this uncharted territory of mRNA-based immunization strategies, we stand at the precipice of a profound transformation in vaccinology. Recent studies and research have illuminated a path forward, one marked by rapid development, adaptability, and potential for highly targeted interventions.[19] However, addressing the associated challenges and ensuring equitable access to these transformative vaccines will be pivotal as we seek to harness the full potential of mRNA-based immunization strategies. In this dynamic landscape, the convergence of science, technology, and global collaboration promises a brighter future, where vaccines are not only our shield against infectious diseases but also a powerful tool in the fight against cancer and emerging health threats.[20]

1. The RNA Revolution in Molecular Biology

Recent years have witnessed a profound transformation in our understanding of RNA, transitioning from a passive messenger in the central dogma of biology to a dynamic and central player. [21.22] This transformation, often referred to as the "RNA revolution," is rooted in the recognition that messenger RNA (mRNA) is far more than a mere messenger. Instead, it serves as a critical conduit for genetic information, ferrying instructions from DNA in the cell nucleus to the

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 5 Sep-Oct 2023, pp: 833-840 www.ijprajournal.com ISSN: 2249-7781

ribosomes, where protein synthesis occurs.[23] This newfound appreciation for the central role of mRNA has opened the door to innovative applications in vaccine development and beyond. Recent studies have deepened our understanding of mRNA's fundamental role in biology, highlighting its role in mediating gene expression, responding to cellular cues, and serving as a target for therapeutic interventions. [24,25] The adaptability and programmability of mRNA make it a versatile tool, capable of encoding specific proteins, including antigens, and instructing host cells to produce these proteins. This revolutionary potential has catalyzed the exploration of mRNA-based immunization strategies. [26,27]

2. mRNA Vaccines Defined

At their core, mRNA vaccines are a novel class of vaccines that leverage synthetic mRNA molecules to encode target antigens. When administered, these synthetic mRNA molecules serve as templates for antigen production within host cells.[28] This process initiates immune responses against the encoded antigens, ultimately protecting the target pathogen.[29] The design of mRNA vaccines offers several advantages over traditional vaccine approaches. Unlike live attenuated or inactivated vaccines, mRNA vaccines do not require the cultivation and manipulation of pathogens, reducing the associated safety concerns. Moreover, mRNA vaccines provide a rapid response platform, enabling the development of vaccines in a shorter timeframe, a crucial factor in the face of emerging infectious diseases. [30,31]



Fig 1. mRNA Vaccine Mechanism [61]



Fig 2. Vaccine Production Protocol

3. COVID-19 mRNA Vaccines as Pioneers

The global COVID-19 pandemic presented an unprecedented challenge, demanding the rapid development of safe and effective vaccines. In this critical context, mRNA vaccines emerged as pioneers, showcasing their potential to expedite vaccine development without compromising safety or efficacy. [32,33] Two mRNA vaccines, the Pfizer-BioNTech and Moderna vaccines, garnered particular attention and acclaim for their remarkable efficacy in clinical trials. These vaccines achieved efficacy rates that exceeded expectations, providing hope for pandemic control. [34,35] Recent studies have delved into the mechanisms underlying their success, revealing the robust immune responses generated by mRNA-based immunization. The rapid development and authorization of mRNA COVID-19 vaccines marked a historic milestone in vaccinology, demonstrating the versatility and adaptability of this vaccine platform. Moreover, ongoing research continues to assess their long-term safety and efficacy, providing valuable insights into the enduring impact of mRNA vaccines. [36,37]

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 5 Sep-Oct 2023, pp: 833-840 www.ijprajournal.com ISSN: 2249-7781

4. Expanding Applications of mRNA Vaccines

Beyond their pivotal role in addressing the COVID-19 pandemic, mRNA vaccines are extending their reach into other domains of healthcare, including personalized cancer immunotherapy and the response to emerging infectious diseases.[38] Recent research studies have illuminated the therapeutic potential of mRNA vaccines in the field of oncology. By encoding tumor-specific antigens, mRNA vaccines can stimulate immune responses targeted specifically at cancer cells.[39] This personalized approach represents a promising frontier in cancer treatment, offering the potential for highly tailored interventions that harness the patient's immune system to combat malignancies. Furthermore, mRNA vaccines have demonstrated their agility in responding to emerging infectious diseases.[40] Recent research highlights their application in the development of vaccines against diseases such as Zika and Ebola.[41] These examples underscore the capacity of mRNA-based vaccine platforms to rapidly adapt to new and unforeseen health threats, providing an important tool in pandemic preparedness.[42]

5. Enhancing Immunogenicity and Stability

Advancements in mRNA vaccine technology have focused on enhancing immunogenicity and stability. Recent research endeavors have explored innovations in lipid nanoparticles, mRNA modification techniques, and antigen design to optimize vaccine performance. Lipid nanoparticles, which encapsulate and protect mRNA molecules, have been a focal point of research.[43] These nanoparticles play a crucial role in vaccine delivery, ensuring the efficient uptake of mRNA by host cells. Ongoing studies aim to refine lipid nanoparticle formulations, enhancing their stability and effectiveness. Additionally, research efforts have delved into modifying mRNA molecules to improve their performance as vaccine templates.[44] Recent studies have explored modifications to enhance mRNA stability, translation efficiency, and antigen expression. [45,16] These modifications contribute to the overall immunogenicity and efficacy of mRNA vaccines. Antigen design is another critical aspect of mRNA vaccine optimization. Recent research has sought to identify and refine antigen targets that elicit robust and long-lasting immune responses. This process involves the selection of antigen sequences and structures that maximize vaccine effectiveness.[47]

6. Challenges and Future Directions

While the promise of mRNA-based immunization strategies is undeniably bright, several challenges and future directions warrant consideration

Storage and Distribution: The need for ultra-low-temperature storage presents logistical challenges, particularly in resource-limited settings. Ongoing research seeks to address these issues through improved storage and distribution strategies, including the development of stable vaccine formulations. [48,49]

Safety and Allergic Reactions: Reports of rare adverse events, such as anaphylaxis, have raised safety concerns with mRNA vaccines.[50] Recent research is focused on investigating the underlying mechanisms and risk factors associated with these events, informing strategies for mitigation and patient selection. [51,52]

Equitable Access: Ensuring equitable access to mRNA vaccines on a global scale is imperative. [53] Recent research underscores the importance of global collaboration. [54,55]

II. CONCLUSION

In the ever-evolving landscape of vaccinology, mRNA-based immunization strategies have emerged as a transformative force, marked by recent studies and research that illuminate their vast potential. The journey through the intricacies of mRNA vaccines, from their origins in the RNA revolution to their application in pandemics and cancer treatment, underscores the remarkable adaptability and versatility of this vaccine platform. The RNA revolution, which elevated mRNA from a passive messenger to a central player in molecular biology, serves as the foundation upon which mRNA vaccines have been built. Recent studies have deepened our understanding of mRNA's roles in gene expression, cellular responses, and therapeutic interventions, culminating in the innovative approach of mRNA-based vaccines. The defining characteristic of mRNA vaccines is their ability to harness synthetic mRNA molecules to encode target antigens, instructing host cells to produce these antigens and stimulate robust immune responses.[55] This ingenious strategy offers several advantages, including rapid development timelines and flexibility in vaccine design. Recent research has illuminated the underlying mechanisms of mRNA vaccine success, exemplified by the Pfizer-BioNTech and Moderna COVID-19 vaccines, which have achieved unprecedented efficacy rates.

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 5 Sep-Oct 2023, pp: 833-840 www.ijprajournal.com ISSN: 2249-7781

The global response to the COVID-19 pandemic showcased the transformative potential of mRNA vaccines. These vaccines emerged as pioneers, delivering a swift and effective response to the novel coronavirus. Their authorization marked a historic moment in vaccinology, validating the adaptability and safety of mRNA-based immunization strategies.[56] Ongoing research continues to unravel the intricacies of long-term vaccine efficacy and safety. Beyond their role in infectious disease control, mRNA vaccines have ventured into the realm of personalized cancer immunotherapy. Recent studies underscore their therapeutic potential, as mRNA vaccines encoding tumor-specific antigens stimulate immune responses targeted explicitly at cancer cells. This promising approach represents a paradigm shift in cancer treatment, offering personalized interventions that harness the patient's immune system against malignancies. Moreover, mRNA vaccines have demonstrated their adaptability in responding to emerging infectious diseases, exemplified by their application in the development of vaccines against Zika and Ebola. This nimble response capability positions mRNA-based vaccine platforms as crucial tools in pandemic preparedness. Advancements in mRNA vaccine technology continue to enhance their immunogenicity and stability.[57] Research efforts have focused on lipid nanoparticles, mRNA modifications, and antigen design to optimize vaccine performance. These innovations contribute to the overall efficacy and effectiveness of mRNA vaccines, further solidifying their role in future vaccine development. However, as we navigate this promising landscape, challenges and future directions demand our attention. Storage and distribution logistics, including the need for ultra-low-temperature storage, pose logistical hurdles that require innovative solutions.[58] Safety concerns, highlighted by rare adverse events, necessitate ongoing research to understand underlying mechanisms and implement mitigation strategies. Ensuring equitable global access to mRNA vaccines remains a paramount ethical concern, emphasizing the importance of international collaboration and technology transfer. In conclusion, recent research studies have illuminated a transformative path forward in vaccinology through mRNA-based immunization strategies.[59] These strategies promise to reshape our approach to infectious diseases, cancer treatment, and pandemic preparedness. Yet, our journey is not without challenges, and addressing these challenges while ensuring equitable access will be pivotal as we seek to harness the full potential of mRNA-based immunization. In this dynamic landscape, science, technology, and global collaboration converge to usher in a brighter future, where vaccines serve as not only shields against diseases but also potent tools in advancing human health and well-being.[60]

III. ACKNOWLEDGMENT

The authors wish to extend their heartfelt gratitude to two esteemed individuals whose invaluable contributions played a pivotal role in enhancing the quality of this manuscript. Dr. B. S. Yadav, the erudite Principal of K. J. Somaiya College of Arts, Commerce, and Science in Kopargaon, and Prof. Prajakta Deshpande, a distinguished member of the Department of Zoology at H.P.T. Art's and R.Y.K. Science College in Nashik, Maharashtra, India, deserve special recognition.

REFERENCES

[1]. Adegbola, R. A., & Saha, D. (2010). Vaccines: A Cost-Effective Strategy to Contain Antimicrobial Resistance. Antimicrobial Resistance in Developing Countries, 477-490.

[2]. McMillen, C. W. (2015). Discovering tuberculosis: a global history, 1900 to the present. Yale University Press.

[3]. Vincent, A. L., Perez, D. R., Rajao, D., Anderson, T. K., Abente, E. J., Walia, R. R., & Lewis, N. S. (2017). Influenza A virus vaccines for swine. Veterinary microbiology, 206, 35-44.

[4]. Chen, S., Huang, X., Xue, Y., Álvarez-Benedicto, E., Shi, Y., Chen, W., ... & Tao, W. (2023). Nanotechnology-based mRNA vaccines. Nature Reviews Methods Primers, 3(1), 63.

[5]. Gourbal, B., Pinaud, S., Beckers, G. J., Van Der Meer, J. W., Conrath, U., & Netea, M. G. (2018). Innate immune memory: An evolutionary perspective. Immunological Reviews, 283(1), 21-40.

[6]. Sztuba-Solinska, J., Chavez-Calvillo, G., & Cline, S. E. (2019). Unveiling the druggable RNA targets and small molecule therapeutics. Bioorganic & medicinal chemistry, 27(10), 2149-2165.

[7]. Yang, B., Chen, Y., & Shi, J. (2019). Exosome biochemistry and advanced

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 5 Sep-Oct 2023, pp: 833-840 www.ijprajournal.com ISSN: 2249-7781

nanotechnology for next-generation theranostic platforms. Advanced Materials, 31(2), 1802896.

[8]. Harisa, G. I., Faris, T. M., Sherif, A. Y., Alzhrani, R. F., Alanazi, S. A., Kohaf, N. A., & Alanazi, F. K. (2023). Coding Therapeutic Nucleic Acids from Recombinant Proteins to Next-Generation Vaccines: Current Uses, Limitations, and Future Horizons. Molecular Biotechnology, 1-19.

[9]. Vijayan, V., Mohapatra, A., Uthaman, S., & Park, I. K. (2019). Recent advances in nanovaccines using biomimetic immunomodulatory materials. Pharmaceutics, 11(10), 534.

[10]. Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021). Novel approaches for vaccine development. Cell, 184(6), 1589-1603.

[11]. Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021). From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Molecular Aspects of Medicine, 81, 101003.

[12]. Wang, Y., Chen-Mayfield, T. J., Li, Z., Younis, M. H., Cai, W., & Hu, Q. (2022). Harnessing DNA for immunotherapy: cancer, infectious diseases, and beyond. Advanced Functional Materials, 32(37), 2112273.

[13]. Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., ... & Steinmetz, N. F. (2020). COVID-19 vaccine development and a potential nanomaterial path forward. Nature nanotechnology, 15(8), 646-655.

[14]. Barbuddhe, S. B., Rawool, D. B., Gaonkar, P. P., Vergis, J., Dhama, K., & Malik, S. S. (2020). Global scenario, public health concerns and mitigation strategies to counter current ongoing SARS-CoV-2/COVID-19 pandemic. Human Vaccines & Immunotherapeutics, 16(12), 3023-3033.

[15]. Rehman, N., & Pandey, A. (2021). An Overview of COVID-19 and Its Vaccines. Biology Bulletin Reviews, 11(Suppl 1), 47-64.

[16]. Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M., ... & Nadeau, K. C. (2021). Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives. Allergy, 76(6), 1640-1660.

[17]. Szebeni, J., Storm, G., Ljubimova, J. Y., Castells, M., Phillips, E. J., Turjeman, K., ... & Dobrovolskaia, M. A. (2022). Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines. Nature nanotechnology, 17(4), 337-346.

[18]. Ding, M., Dong, X., Sun, Y. L., Sokolowska, M., Akdis, M., van de Veen, W., ... & Gao, Y. D. (2021). Recent advances and developments in COVID-19 in the context of allergic diseases. Clinical and Translational Allergy, 11(7), e12065.

[19]. Oueijan, R. I., Hill, O. R., Ahiawodzi, P. D., Fasinu, P. S., & Thompson, D. K. (2022). Rare Heterogeneous Adverse Events Associated with mRNA-Based COVID-19 Vaccines: A Systematic Review. Medicines, 9(8), 43.

[20]. Heidari, S., Durrheim, D. N., Faden, R., Kochhar, S., MacDonald, N., Olayinka, F., & Goodman, T. S. (2021). Time for action: towards an intersectional gender approach to COVID-19 vaccine development and deployment that leaves no one behind. BMJ Global Health, 6(8), e006854.

[21]. Kounis, N. G., Koniari, I., de Gregorio, C., Velissaris, D., Petalas, K., Brinia, A., ... & Hung, M. Y. (2021). Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines, 9(3), 221.

[22]. Wang, Q., Yang, Y., Lu, G., Sun, X., Feng, Y., Yan, S., ... & Chen, R. (2020). Genome-wide identification of microRNAs and phased siRNAs in soybean roots under long-term salt stress. Genes & genomics, 42, 1239-1249.

[23]. Bazin, J., Baerenfaller, K., Gosai, S. J., Gregory, B. D., Crespi, M., & Bailey-Serres, J. (2017). Global analysis of ribosome-associated noncoding RNAs unveils new modes of translational regulation. Proceedings of the National Academy of Sciences, 114(46), E10018-E10027.

[24]. Webb, C., Ip, S., Bathula, N. V., Popova, P., Soriano, S. K., Ly, H. H., ... &

International Journal of Pharmaceutical Research and Applications
Volume 8, Issue 5 Sep-Oct 2023, pp: 833-840 www.ijprajournal.com ISSN: 2249-7781

Blakney, A. K. (2022). Current status and future perspectives on mRNA drug manufacturing. Molecular Pharmaceutics, 19(4), 1047-1058.

[25]. Cella, F., Wroblewska, L., Weiss, R., & Siciliano, V. (2018). Engineering protein-protein devices for multilayered regulation of mRNA translation using orthogonal proteases in mammalian cells. Nature Communications, 9(1), 4392.

[26]. Costa, V. G., Costa, S. M., Saramago, M., Cunha, M. V., Arraiano, C. M., Viegas, S. C., & Matos, R. G. (2022). Developing new tools to fight human pathogens: A journey through the advances in RNA technologies. Microorganisms, 10(11), 2303.

[27]. Ono, H., Kawasaki, S., & Saito, H. (2019). Orthogonal protein-responsive mRNA switches for mammalian synthetic biology. ACS Synthetic Biology, 9(1), 169-174.

[28]. Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature reviews Drug discovery, 20(11), 817-838.

[29]. Chehelgerdi, M., & Chehelgerdi, M. (2023). The use of RNA-based treatments in the field of cancer immunotherapy. Molecular Cancer, 22(1), 106.

[30]. Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022). The landscape of mRNA nanomedicine. Nature Medicine, 28(11), 2273-2287.

[31]. Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022). The clinical progress of mRNA vaccines and immunotherapies. Nature biotechnology, 40(6), 840-854.

[32]. Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., ... & Badaró, R. (2021). The importance of RNA-based vaccines in the fight against COVID-19: an overview. Vaccines, 9(11), 1345.

[33]. Semple, S. C., Leone, R., Barbosa, C. J., Tam, Y. K., & Lin, P. J. (2022). Lipid nanoparticle delivery systems to enable mRNA-based therapeutics. Pharmaceutics, 14(2), 398.

[34]. World Health Organization. (2021). COVID-19 vaccines: safety surveillance manual.

[35]. Rinoldi, C., Zargarian, S. S., Nakielski, P., Li, X., Liguori, A., Petronella, F., ... & Pierini, F. (2021). Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines. Small Methods, 5(9), 2100402.

[36]. Schwalb, A., Armyra, E., Méndez-Aranda, M., & Ugarte-Gil, C. (2022). COVID-19 in Latin America and the Caribbean: two years of the pandemic. Journal of internal medicine, 292(3), 409-427.

[37]. Lee, P. (2022). Patents and the Pandemic: Intellectual Property, Social Contracts, and Access to Vaccines: 2021 Shidler Lecture. Wash. JL Tech. & Arts, 17, 193.

[38]. Zhou, Y. W., Xie, Y., Tang, L. S., Pu, D., Zhu, Y. J., Liu, J. Y., & Ma, X. L. (2021). Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Signal transduction and targeted therapy, 6(1), 317.

[39]. Feng, C., Li, Y., Ferdows, B. E., Patel, D. N., Ouyang, J., Tang, Z., ... & Tao, W. (2022). Emerging vaccine nanotechnology: From defense against infection to sniping cancer. Acta Pharmaceutica Sinica B, 12(5), 2206-2223.

[40]. Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022). The clinical progress of mRNA vaccines and immunotherapies. Nature biotechnology, 40(6), 840-854.

[41]. Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M., ... & Huang, Y. (2022). mRNA vaccines for COVID-19 and diverse diseases. Journal of Controlled Release, 345, 314-333.

[42]. Wang, Y., Chen-Mayfield, T. J., Li, Z., Younis, M. H., Cai, W., & Hu, Q. (2022). Harnessing DNA for immunotherapy: cancer, infectious diseases, and beyond. Advanced Functional Materials, 32(37), 2112273.

[43]. Pilkington, E. H., Suys, E. J., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., ... & Truong, N. P. (2021). From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the

frontiers of infectious diseases. Acta biomaterialia, 131, 16-40.

[44]. Chehelgerdi, M., & Chehelgerdi, M. (2023). The use of RNA-based treatments in the field of cancer immunotherapy. Molecular Cancer, 22(1), 106.

[45]. Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. Nature reviews Drug discovery, 17(4), 261-279.

[46]. Yang, L., Gong, L., Wang, P., Zhao, X., Zhao, F., Zhang, Z., ... & Huang, W. (2022). Recent advances in lipid nanoparticles for delivery of mRNA. Pharmaceutics, 14(12), 2682.

[47]. Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature reviews Drug discovery, 20(11), 817-838.

[48]. Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020). Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics, 12(2), 102.

[49]. Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022). The clinical progress of mRNA vaccines and immunotherapies. Nature biotechnology, 40(6), 840-854.

[50]. Chavda, V. P., Soni, S., Vora, L. K., Soni, S., Khadela, A., & Ajabiya, J. (2022). mRNA-based vaccines and therapeutics for COVID-19 and future pandemics. Vaccines, 10(12), 2150.

[51]. Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019). mRNA as a transformative technology for vaccine development to control infectious diseases. Molecular Therapy, 27(4), 757-772.

[52]. Piché-Renaud, P. P., Morris, S. K., & Top, K. A. (2023). A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID-19 mRNA vaccination. British Journal of Clinical Pharmacology, 89(3), 967-981.

[53]. Oladipo, E. K., Olufemi, S. E., Ojo, T. O., Adediran, D. A., Idowu, A. F., Idowu, U. A., & Onyeaka, H. (2023). Africa (COVID-19) Vaccine Technology Transfer: Where Are We?. Life, 13(9), 1886.

[54]. Boschiero, N. (2021). COVID-19 vaccines as global common goods: An integrated approach of ethical, economic policy and intellectual property management. Global Jurist, 22(2), 177-230.

[55]. da Fonseca, E. M., Shadlen, K. C., & de Moraes Achcar, H. (2023). Vaccine technology transfer in a global health crisis: Actors, capabilities, and institutions. Research Policy, 52(4), 104739.

[56]. Buonaiuto, G., Desideri, F., Taliani, V., & Ballarino, M. (2021). Muscle regeneration and RNA: new perspectives for ancient molecules. Cells, 10(10), 2512.

[57]. Sideras, K., Braat, H., Kwekkeboom, J., Van Eijck, C. H., Peppelenbosch, M. P., Sleijfer, S., & Bruno, M. (2014). Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer treatment reviews, 40(4), 513-522.

[58]. Pilkington, E. H., Suys, E. J., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., ... & Truong, N. P. (2021). From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta biomaterialia, 131, 16-40.

[59]. Chehelgerdi, M., & Chehelgerdi, M. (2023). The use of RNA-based treatments in the field of cancer immunotherapy. Molecular Cancer, 22(1), 106.

[60]. Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., ... & Song, X. (2022). mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal transduction and targeted therapy, 7(1), 166.

[61]. Park JW, Lagniton PNP, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci 2021; 17(6):1446-1460. doi:10.7150/ijbs.59233. https://www.ijbs.com/v17p1446.htm